Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

ABACIOGLU M. U., Yumuk P., Caglar H., Sengoz M., Turhal N.

BMC CANCER, cilt.5, 2005 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1186/1471-2407-5-71
  • Dergi Adı: BMC CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC.